Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange - Seite 2
About the London Stock Exchange
The London Stock Exchange was founded in 1571 during the reign of Elizabeth I in London, England. The LSE is the 4th largest exchange in the world (based on total market value of its listed
companies) and is currently ranked 7th in overall liquidity. As of August 2020, the companies listed on the London Stock Exchange have a combined market capitalisation of ~$4 trillion USD (GBP
~£3,084,232,000,000). Its current premises are situated in Paternoster Square close to St Paul's Cathedral. It is part of publicly traded London Stock Exchange Group (LSEG).
About Boustead & Company Limited
Boustead & Company Limited is a diversified and comprehensive non-bank financial institution with offices in Los Angeles, New York, San Francisco, London, and Beijing that is rapidly expanding
in growth markets throughout the US and Asia. Through its principals and fully licensed subsidiaries, Boustead & Company possesses rich experience and exceptional capabilities in capital
markets deal execution and provides best-in-class one-stop financial services to clients. Boustead’s comprehensive financial services platform consists of four operating units: Boustead Securities,
LLC a US-based FINRA Broker/Dealer and middle-market investment bank; Sutter Securities Group, Inc., which owns four FINRA-regulated entities: Sutter Securities, Inc., Sutter Securities Clearing,
LLC and FlashFunders Funding Portal, LLC, along with Sutter Securities Financial Services, Inc., Sutter Capital Partners, LLC a California Registered Investment Advisor; and Boustead Capital
Markets LLP, regulated as an appointed representative in the UK. For more information, please visit www.bousteadco.com.
On behalf of Boustead & Company
Limited
Dan McClory, CEO
dan@boustead1828.com
About Boustead Capital Markets, LLP
Boustead Capital Markets, LLP, based in London, advises on a wide array of corporate finance assignments across many industries, and is an appointed representative of Thornbridge Investment
Management LLP which is authorised and regulated by the FCA. Boustead Capital Markets is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial
institution.
On behalf of Boustead Capital Markets,
LLP
David Peerless, Director
david@boustead1828.com
Lesen Sie auch
About Mydecine Innovations Group Inc.
Mydecine Innovations Group (CSE: MYCO) is a publicly traded life sciences syndicate, with offices in Denver, CO, USA and Vancouver, BC, Canada. Mydecine is dedicated to the
development and production of adaptive pathway medicine and natural health products all stemming from mushrooms. Mydecine’s experienced multi-talented team has the dynamic capabilities to oversee
all areas of Schedule I drug development, including but not limited to synthesis, genetic research, delivery mechanism design, clinical trial execution; through to worldwide product
commercialization, marketing and spore-to-sale distribution of cGMP psilocybin API’s and non-psychedelic medicinal fungi. By leveraging strategic partnerships with global scientific, medical,
clinical, and Veteran organizations; Mydecine is well positioned at the forefront of naturally derived medicine, alternative therapeutics, and fungtional mushroom vitality consumer goods. Our
portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health, and NeuroPharm focus together on providing innovative and effective solutions that can help millions of people
live a healthier quality life.